BioCentury
ARTICLE | Company News

Elan, Spectral Diagnostics deal

July 21, 2003 7:00 AM UTC

The companies ended their 1998 deal to develop and commercialize sepsis assays including SDI's Endotoxin Activity Assay (EAA), which is marketed to identify patients at risk for developing severe sep...